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Abstract
These studies probed the relationship between intrinsic efficacy and tolerance / cross-tolerance 
between Δ9-THC and synthetic cannabinoid drugs of abuse (SCBs) by examining in vivo effects 
and cellular changes concomitant with their repeated administration in mice. Dose-effect 
relationships for hypothermic effects were determined in order to confirm that SCBs JWH-018 
and JWH-073 are higher efficacy agonists than Δ9-THC in mice. Separate groups of mice were 
treated with saline, sub-maximal hypothermic doses of JWH-018 or JWH-073 (3.0 mg/kg or 10.0 
mg/kg, respectively) or a maximally hypothermic dose of 30.0 mg/kg Δ9-THC once per day for 5 
consecutive days while core temperature and locomotor activity were monitored via biotelemetry. 
Repeated administration of all drugs resulted in tolerance to hypothermic effects, but not 
locomotor effects, and this tolerance was still evident 14 days after the last drug administration. 
Further studies treated mice with 30.0 mg/kg Δ9-THC once per day for 4 days, then tested with 
SCBs on day 5. Mice with a Δ9-THC history were cross-tolerant to both SCBs, and this cross-
tolerance also persisted 14 days after testing. Select brain regions from chronically treated mice 
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were examined for changes in CB1 receptor expression and function. Expression and function of 
hypothalamic CB1Rs were reduced in mice receiving chronic drugs, but cortical CB1R expression 
and function were not altered. Collectively, these data demonstrate that repeated Δ9-THC, 
JWH-018 and JWH-073 can induce long-lasting tolerance to some in vivo effects, which is likely 
mediated by region-specific downregulation and desensitization of CB1Rs.
Graphical abstract
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1. Introduction
In recent years, high efficacy synthetic cannabinoids (SCBs) have proliferated as 
psychoactive constituents in commercial smoking preparations, typically advertised as 
“marijuana alternatives” or “herbal incense” and usually branded as K2 or Spice. Product 
surveillance and analytical testing have detected numerous formulations for these 
cannabinoids, including powders, capsules, liquids, and smoking mixtures (Verster, 2010; 
Seely et al., 2013). Among the first synthetic cannabinoids detected in these products were 
JWH-018 (1-pentyl-3-(1-naphthoyl)indole) and JWH-073 (1-butyl-3-(1-naphthoyl)indole), 
both of which bind with high affinity and act as full agonists at cannabinoid type 1 receptors 
(CB1Rs) (Huffman et al., 1994). Since the initial appearance of these products on the illicit 
market, product composition has rapidly changed in order to stay ahead of drug scheduling 
laws. Thus, in addition to a number of Huffman aminoalkylindoles (the “JWH” series), other 
synthetic cannabinoids including the Δ9-THC analogue HU-210 (1,1-dimethylheptyl-11-
hydroxytetrahydrocannabinol), a number of cyclohexylphenols (including CP-47,497 and 
CP-55,940), and several other indole-derived cannabinoids (such as the fluorinated analogue 
of JWH-018, AM-2201) have also been detected (Seely et al., 2012). Despite the diversity of 
the psychoactive constituents of these products, a common feature has been their higher 
CB1R efficacy, as compared to the partial CB1R agonist Δ9-THC.
Repeated administration of cannabinoid agonists has been shown to result in tolerance to 
several central and peripheral effects in laboratory animals (Dewey, 1986; Abood and 
Martin, 1992; Maldonado and Rodriguez de Fonseca, 2002), and to cellular effects observed 
in vitro (reviewed by Pertwee, 1991). In human marijuana users, tolerance to numerous 
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cannabinoid effects has also been reported following smoked (Jones et al., 1981; Hollister, 
1986; Ramaekers et al., 2011) and oral (Benowitz and Jones, 1975; Hunt and Jones, 1980; 
Gorelick et al., 2013) administration of Δ9-THC. This raises the possibility that a history of 
Δ9-THC administration might also render individuals less sensitive to some effects of the 
higher efficacy SCBs through the phenomenon of cross-tolerance. However, much of what 
is known regarding tolerance to drug effects comes from the study of opioids, where 
intrinsic efficacy is a critical factor in both the development of tolerance and the degree of 
cross-tolerance observed across in vivo effects (Paronis and Holtzman, 1992; Walker and 
Young, 2001). In this regard, tolerance to specific opioid effects induced by repeated 
treatment with a high efficacy agonist elicit even greater cross-tolerance when low efficacy 
drugs are tested, while tolerance to specific drug effects produced by treatment with a low 
efficacy agonist can be at least partially surmounted by administration of a high efficacy 
compound. But whether this relationship between tolerance, cross-tolerance, and intrinsic 
efficacy extends to cannabinoids remains largely unknown.
In order to better understand the relationship between intrinsic efficacy and tolerance/cross-
tolerance among the cannabinoids, the present studies utilized radiotelemetry to 
simultaneously monitor core temperature and locomotor activity in mice receiving daily 
treatments of Δ9-THC, JWH-018 or JWH-073 (Figure 1) to determine the development and 
expression of tolerance to these two classical effects of the well-characterized “cannabinoid 
tetrad” (Compton et al., 1992). In separate cross-tolerance experiments, the hypothermic and 
locomotor effects of JWH-018 and JWH-073 were assessed in mice with or without a prior 
history of Δ9-THC administration. Mechanisms for changes in drug effects following 
repeated administration were investigated using brain tissue harvested from drug-naïve or 
Δ9-THC-treated mice. Ex vivo assays of CB1R expression and function were performed in 
hypothalamus and cortex, as these brain regions at least partially mediate the 
thermoregulatory and locomotor effects, respectively, studied in mice. As reports of toxicity 
and mortality related to illicit use of synthetic cannabinoids accumulate (Auwarter et al., 
2009; Zimmermann et al., 2009; Every-Palmer, 2010; Muller et al., 2010; Vardakou et al., 
2010; Vearrier and Osterhoudt, 2010; Schneir et al., 2011; Gunderson et al., 2012; Seely et 
al., 2012; Nacca et al., 2013), it is critical to better understand the mechanisms of tolerance 
associated with repeated cannabinoid exposure. As with other classes of abused drugs, 
including benzodiazepines (Lalive et al., 2011), opioids (Morgan and Christie, 2011), and 
psychostimulants (Bradberry, 2002), tolerant users of synthetic cannabinoids may also 
attempt to overcome diminished drug effects by escalating dose, thereby dramatically 
increasing exposure and the concomitant risk of toxicity.
2. Materials and Methods
2.1 Animals
Prior to surgery (see section 2.2), male NIH Swiss mice (Harlan Sprague Dawley Inc., 
Indianapolis, IN), weighing approximately 25–30 g, were housed 3 animals per Plexiglas 
cage (15.24 × 25.40 × 12.70 cm) in a temperature-controlled room at the University of 
Arkansas for Medical Sciences. Room conditions were maintained at an ambient 
temperature of 22 ± 2°C at 45–50% humidity. Lights were set to a 12-h light/dark cycle. 
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Animals were fed Lab Diet rodent chow (Laboratory Rodent Diet #5001, PMI Feeds, Inc., 
St. Louis, MO) and water ad libitum until immediately before testing. Animals were 
acclimated to the laboratory environment 2 days prior to experiments and were tested in 
groups of 5–6 mice per condition. All studies were carried out in accordance with the 
Declaration of Helsinki and with the Guide for Care and Use of Laboratory animals as 
adopted and promulgated by the National Institutes of Health. Experimental protocols were 
approved by the Animal Care and Use Committee at the University of Arkansas for Medical 
Sciences.
2.2 Core Temperature and Locomotor Activity
Following appropriate anesthetization with inhaled isoflurane, the abdominal area of each 
mouse was shaved and sanitized with iodine swabs. A rostro-caudal cut approximately 1.5 
cm in length was made with skin scissors, providing access to the intraperitoneal cavity. A 
cylindrical glass-encapsulated radiotelemetry probe (model ER-4000 E-Mitter, Mini Mitter, 
Bend, OR, USA) was then inserted, and the incision was closed using absorbable 5–0 
chromic gut suture material. At least 7 days were imposed between surgery and 
experimental observation of drug effects to allow incisions to heal and mice to recover to 
normal body weights. Following surgery, implanted mice were individually housed in 
Plexiglas mouse cages (15.24 × 25.40 × 12.70 cm) for the duration of all temperature and 
locomotor activity experiments. Implanted transmitters produced activity- and temperature-
modulated signals that were transmitted to a receiver (model ER-4000 Receiver, Mini Mitter 
Co., Inc.) underneath each mouse cage. Receivers were housed in light- and sound-
attenuating cubicles (Med Associates model ENV-022MD, St. Albans, VT) equipped with 
exhaust fans, which further masked ambient laboratory noise. Temperature and locomotor 
activity data were collected simultaneously at regular 5-min intervals and processed by the 
Vital View data acquisition system (Mini Mitter Co., Inc.).
For dose-effect determinations, mice were weighed, marked, and returned to their individual 
cages during which at least 1 hr of baseline data were collected. Cannabinoid doses were 
then calculated and drugs prepared for injection. Animals were subsequently removed from 
their cage and injected with saline, or various doses of Δ9-THC, JWH-018 or JWH-073. 
Mice were placed into a new cage with fresh bedding to stimulate exploratory behavior, 
providing an elevated activity baseline from which a drug-induced suppression of locomotor 
activity could be characterized, then returned to the telemetry chambers for approximately 
24 hrs of data collection. Separate groups of mice (n=5) were tested at each dose condition 
for each compound.
To assess tolerance to hypothermic and locomotor effects, four groups of mice (n=5) were 
injected daily with either saline, 30 mg/kg Δ9-THC, 3 mg/kg JWH-018, or 10 mg/kg 
JWH-073 for 5 consecutive days, and data were collected continuously until 24 hrs after the 
last injection. After 5 days of data collection was completed, injections were suspended for 
14 days, then mice were retested with the same dose of the same cannabinoid to assess the 
persistence of tolerance. For studies involving cross-tolerance among Δ9-THC and the 
SCBs, mice were injected daily with 30 mg/kg Δ9-THC for 4 consecutive days, then tested 
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with either 3 mg/kg JWH-018 or 10 mg/kg JWH-073 on day 5, and again after 14 days of 
drug abstinence.
2.3 Membrane Preparation
Four groups of mice (n=6) were injected daily with drug vehicle (see section 2.6), 30 mg/kg 
Δ9-THC, 3 mg/kg JWH-018, or 10 mg/kg JWH-073 for 4 consecutive days. Twenty four 
hours after the last injection, mice were euthanized by cervical dislocation and decapitation. 
Whole brains were immediately removed and hypothalamus and cortex regions were hand 
dissected out on ice, then snap-frozen in liquid nitrogen and stored at −80°C. Thus, all in 
vitro studies were performed in brain homogenates at a drug state equivalent to that in mice 
used in tolerance studies just prior to the 5th consecutive cannabinoid injection (see section 
2.2).
To prepare membrane homogenates, brains were thawed on ice, pooled and suspended in 
ice-cold homogenization buffer (50 mM HEPES pH 7.4, 3 mM MgCl2, and 1 mM EGTA) 
(Prather et al., 2000). Suspended brain regions were then subjected to 10 complete strokes 
employing a 40 mL Dounce glass homogenizer, and centrifuged at 40,000 × g for 10 min at 
4°C. Supernatants were discarded and pellets were resuspended in ice cold homogenization 
buffer, homogenized and centrifuged similarly twice more. Following the final 
centrifugation step, pellets were resuspended in ice-cold 50 mM HEPES, pH 7.4, to a 
concentration of approximately 2 mg/mL and aliquoted for storage at −80°C. Protein 
concentration was determined using BCA™ Protein Assay (Thermo Scientific, Rockford, 
IL).
2.4 Competition Receptor Binding
Fifty µg of mouse hypothalamic or cortical membrane homogenates (containing a relatively 
pure source of CB1Rs) were incubated with 1.0 nM of the radiolabeled cannabinoid agonist 
[3H]CP-55,940 for 90 min at room temperature in an assay buffer containing 5 mM MgCl2, 
50 mM Tris, 0.05% bovine serum albumin (BSA). Assays were performed in triplicate, in a 
final volume of 1 mL, as previously described (Shoemaker et al., 2005). Total binding was 
defined as the amount of radioactivity observed when 1.0 nM [3H]CP-55,940 was incubated 
in tissues from vehicle-treated mice. Nonspecific binding was defined as the amount of 
[3H]CP-55,940 binding remaining in the presence of 1 µM of the non-radioactive CB1/
CB2R agonist WIN-55,212-2. Specific binding was calculated by subtracting non-specific 
from total binding. Reactions were terminated by rapid filtration through Whatman GF/B 
glass fiber filters, followed by five washes with an ice-cold buffer containing 50 mM Tris 
and 0.05% bovine serum albumin (BSA). Filters were punched out into 7 mL scintillation 
vials and immersed in 4 mL of ScintiVerse™ BD Cocktail scintillation fluid. After 
overnight extraction, bound radioactivity was determined by liquid scintillation 
spectrophotometry. Specific binding is expressed as a percentage of binding occurring in 
vehicle samples (e.g., binding in the absence of any competitor).
2.5 [35S]GTPγS Binding
[35S]GTPγS binding was performed as previously described (Liu and Prather, 2001), with 
minor modifications. JWH-018 (10 µM) was incubated with 25 µg of mouse hypothalamus 
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or cortical membrane homogenates, 10 µM GDP, 0.1 nM [35S]GTPγS and assay buffer (20 
mM HEPES, 10 mM MgCl2, 100 mM NaCl, 20 units/L adenosine deaminase, 0.05% BSA). 
Assays were performed in triplicate in a final volume of 1 mL for 30 min at 30°C. Total 
binding was defined as the amount of radioactivity observed when 0.1 nM [35S]GTPγS was 
incubated in membranes from vehicle-treated mice. Nonspecific binding was defined as the 
amount of [35S]GTPγS binding remaining in the presence of 10 µM of non-radioactive 
GTPγS. Specific binding was calculated by subtracting non-specific from total binding. 
Reactions were terminated by rapid filtration through Whatman GF/B glass fiber filters, 
followed by five washes with an ice-cold buffer containing 20 mM HEPES and 0.05% BSA. 
Filters were punched out into 7 mL scintillation vials and immersed in 4 mL of 
ScintiVerse™ BD Cocktail scintillation fluid. After overnight extraction, bound 
radioactivity was determined by liquid scintillation spectrophotometry. Specific binding is 
expressed as picomoles of [35S]GTPγS bound per mg of protein.
2.6 Drugs
All drugs used for in vitro assays were diluted to a stock concentration of 10−3 M with 100% 
ethanol and stored at −20°C. JWH-018 and JWH-073 were synthesized by Thomas 
Prisinzano, Ph.D. (University of Kansas, Lawrence, KS) and provided to the investigators 
free of charge. Δ9-THC was supplied by the National Institute on Drug Abuse (NIDA, 
Bethesda, MD). GTPγS and GDP used in the [35S]GTPγS assay were purchased from EMD 
Chemical (Gibbstown, NJ), and Sigma Aldrich (St. Louis, MO), respectively. Both 
chemicals were diluted to a stock concentration of 10−2 M with water and stored at −20°C. 
[3H]CP-55,940 (174.6 Ci/mmol) used for competition receptor binding was purchased from 
PerkinElmer (Waltham, MA) and [35S]GTPγS (1250 Ci/mmol) was purchased from 
American Radiolabeled Chemicals (St. Louis, MO). For in vivo studies, all drugs were 
dissolved to the appropriate concentrations in a ratio of 1:1:18 of absolute 
ethanol:emulphor:physiological saline vehicle and stored at 4°C until used. All drugs were 
administered intraperitoneally in mice.
2.7 Data Analysis
All data are presented as group means ± SEM. Points without error bars indicate that the 
variance is contained within the data point. For dose-effect determinations of effects on core 
body temperature, the lowest core temperature measured within 8 hours after injection was 
averaged across animals in a given dose condition, then compared by a Kruskal-Wallis one 
way analysis of variance (ANOVA) on ranks because data were not normally distributed. To 
determine significant differences in hypothermic responses elicited by 30 mg/kg Δ9-THC, 
3.0 mg/kg JWH-018 or 10.0 mg/kg JWH-073 after saline or 30.0 mg/kg Δ9-THC 
pretreatment, an ANOVA was conducted, then all groups were compared to the saline + Δ9-
THC using a Dunnett’s test. For single dose tolerance and cross tolerance studies, repeated 
measures one way ANOVAs were performed on the lowest temperatures achieved by each 
subject, as well as on the times at which core temperatures returned to pre-injection baseline 
(operationally defined as three consecutive readings ≥ 36°C.) Locomotor data were analyzed 
by summing all locomotor counts between 0 and 8 hrs after injection, calculating group 
means, then statistically comparing groups using one way repeated measures ANOVA. For 
consistency in statistical testing across in vivo studies, the Student-Newman-Keuls method 
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was always used to test all pairwise comparisons since this test can be conducted after 
ANOVA or repeated measures ANOVA, and is applicable to normally- and abnormally-
distributed data sets. All in vivo statistical calculations were performed using SigmaStat 3 
(Systat Software, Inc., San Jose, CA), and significance was judged at the level of p < 0.05.
Statistical analyses for ex vivo experiments were performed using GraphPad Prism version 
4.0b (GraphPad Software Inc., San Diego, CA). Data are expressed as mean ± S.E.M. A 
one-way ANOVA, followed by Tukey’s Multiple Comparison post-hoc Test, was used to 
determine statistical significance (P < 0.05) between three or more groups.
3. Results
3.1 Dose-effect determinations of hypothermic effects: apparent in vivo efficacy 
differences between Δ9-THC, JWH-018 and JWH-073
All three cannabinoids decreased core temperature in a dose-dependent manner, with a 
relative order of potency of JWH-018 > JWH-073 > Δ9-THC (Figure 2, left). For all 
compounds, peak hypothermic effects typically occurred within 60–75 minutes after 
injection. The overall ANOVA indicated a significant difference between median values 
(H=55.608, df=12, p<0.05), and significant pairwise comparisons were found within drug 
(between doses, see asterisks in Figure 2, left panel). Importantly, hypothermic effects of 
30.0 and 100.0 mg/kg Δ9-THC induced similar hypothermic effects (p>0.05), indicating a 
maximal effect had been reached, so no further doses were tested.
Significant differences were also detected in pairwise comparisons between drugs (within 
dose, see bullseyes in Figure 2, left panel). At 3.0 mg/kg, hypothermia elicited by JWH-018 
was significantly different from that induced by JWH-073 (q=6.563) and by Δ9-THC 
(q=6.793, p<0.05 for both comparisons), while hypothermic effects of JWH-073 were 
different from those elicited by Δ9-THC (q=5.560, p<0.05). At 10.0 mg/kg, there was no 
significant difference between hypothermic effects of JWH-018 and JWH-073 (p>0.05), but 
both JWH-018 (q=6.255) and JWH-073 (q=6.961) induced hypothermic effects which 
differed from those of Δ9-THC (p<0.05 for both comparisons.) At 30.0 mg/kg, again there 
was no significant difference between hypothermic effects of JWH-018 and JWH-073 
(p>0.05), but both JWH-018 (q=5.499) and JWH-073 (q=4.851) again induced hypothermic 
effects which differed from those of Δ9-THC (p<0.05 for both comparisons.) Importantly, 
the maximal hypothermic effects of both SCBs (observed at 3.0 and 10.0 mg/kg) were 
significantly different from the maximal hypothermic effects of Δ9-THC (observed at 30.0 
and 100.0 mg/kg). Therefore, maximally-effective hypothermic doses of 30.0 mg/kg Δ9-
THC, 3.0 mg/kg JWH-018 and 10.0 mg/kg JWH-073 were used for all subsequent studies 
on tolerance, cross-tolerance and receptor expression and function were conducted with 
these doses.
In blockade studies, mice pretreated with saline (Figure 2, right, open bars) all exhibited 
hypothermic effects when challenged 60 min later with either 30.0 mg/kg Δ9-THC (a 
maximally-effective dose), 3.0 mg/kg JWH-018 or 10.0 mg/kg JWH-073. Importantly, 
pretreatment with 30.0 mg/kg Δ9-THC (Figure 2, right, filled bars) significantly attenuated 
hypothermic effects of JWH-018 and JWH-073, but not those of Δ9-THC. After saline 
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pretreatment, 3.0 JWH-073 (q’=3.286) and 10.0 JWH-073 (q’=3.268, p<0.05 for both 
comparisons) induced significantly different hypothermic effects than 30.0 mg/kg Δ9-THC. 
However, after pretreatment with Δ9-THC, neither 3.0 mg/kg JWH-018 nor 10.0 mg/kg 
JWH-073 induced hypothermic effects which were different from those of 30.0 mg/kg Δ9-
THC.
3.2 Rapid and persistent tolerance to the hypothermic effects of Δ9-THC, JWH-018 and 
JWH-073
Handling, injection of saline, and placement into a new cage with fresh bedding elicited 
mild and relatively brief hyperthermic effects, which were consistently expressed throughout 
the treatment period (Figure 3, upper left). In contrast, the initial administration of all three 
cannabinoids elicited marked hypothermic effects (filled circles in Figure 3, upper right and 
both bottom panels), lasting between 3 and 8 hours, depending on the drug. Importantly, 
with daily administration, a progressive tolerance developed to hypothermic effects of all 
three cannabinoids. For repeated 30.0 mg/kg Δ9-THC administration (Figure 3, upper right), 
significant differences were found in the lowest temperature reached and the time required 
to return to pre-injection baseline temperature (χ2=28.095 and 21.714, respectively, df=5 
and p<0.05 for both tests.) The lowest temperature reached on day 5 was significantly 
different from that observed on day 1 (q=6.110), as was the time required for temperatures 
to return to pre-injection baseline (q=5.237, p<0.05 for both comparisons). Two weeks after 
the fifth Δ9-THC administration, the lowest temperature reached was significantly different 
from that observed on both day 1 (q=4.041) and day 5 (q=5.422, p<0.05 for both 
comparisons), as was the time required for temperatures to return to pre-injection baseline 
(q=2.887 for the comparison with day 1, q=4.906 for the comparison with day 5, p<0.05 for 
both comparisons). For repeated administration of 3.0 mg/kg JWH-018 (Figure 3, bottom 
left), significant differences were found in the lowest temperature reached and the time 
required to return to pre-injection baseline temperature (F=22.361 and χ2=18.529, df=5 and 
p<0.05 for both tests.) The lowest temperature reached on day 5 was significantly different 
from that observed on day 1 (q=12.256), as was the time required for temperatures to return 
to pre-injection baseline (q=4.781, p<0.05 for both comparisons). Two weeks after the fifth 
JWH-018 administration, the lowest temperature reached was significantly different from 
that observed on day 5 (q=8.887, p<0.05) but not from that observed on day 1 (p>0.05), 
although the time required for temperatures to return to pre-injection baseline was 
significantly different from that observed on both day 1 (q=3.795) and day 5 (q=3.960, 
p<0.05 for both comparisons). For repeated administration of 10.0 mg/kg JWH-073 (Figure 
3, bottom right), significant differences were found in the lowest temperature reached and 
the time required to return to pre-injection baseline temperature (F=9.810 and 13.588, df=5 
and p<0.05 for both tests.) The lowest temperature reached on day 5 was significantly 
different from that observed on day 1 (q=6.428), as was the time required for temperatures 
to return to pre-injection baseline (q=5.376, p<0.05 for both comparisons). Two weeks after 
the fifth JWH-073 administration, the lowest temperature reached was significantly different 
from that observed on day 5 (q=5.421, p<0.05) but not from that observed on day 1 
(p>0.05), although the time required for temperatures to return to pre-injection baseline was 
significantly different from that observed on both day 1 (q=2.176) and day 5 (q=7.552, 
p<0.05 for both comparisons).
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3.3 Lack of tolerance to hypolocomotion induced by Δ9-THC, JWH-018 and JWH-073
Handling, injection of saline, and placement into a new cage with fresh bedding elicited 
relatively high levels of motor activity and exploratory behavior during the first 8 hours of 
the baseline observation (“BSLN” point in all panels of Figure 4), one day prior to initiation 
of daily cannabinoid (or saline control) injections. For mice treated daily with saline across 
the treatment period, (Figure 4, upper left) no significant differences from the baseline level 
of motor activity were detected across the treatment period (χ2= 11.929, df=6, p>0.05). In 
contrast, the initial administration of all three cannabinoids elicited marked suppression of 
motor activity (Figure 4, upper right and both bottom panels), and no apparent tolerance to 
this effect developed across the chronic treatment period for any drug. For repeated 30.0 
mg/kg Δ9-THC administration (Figure 4, upper right), the overall ANOVA was significant 
(χ2=25.429, df=5, p<0.05) because every treatment day was significantly different from 
baseline trial (q=5.674, 5.669, 6.957, 8.165 and 5.680 for days 1–5, respectively, and 
q=3.464 for the trial after 2 week abstinence; p<0.05 for all comparisons.) For repeated 3.0 
mg/kg JWH-018 administration (Figure 4, bottom left), the overall ANOVA was significant 
(χ2=21.929, df=5, p<0.05) because every treatment day was significantly different from 
baseline trial (q=5.376, 8.083, 6.047, 6.532 and 5.422 for days 1–5, respectively, and 
q=5.674 for the trial after 2 week abstinence; p<0.05 for all comparisons.) For repeated 10.0 
mg/kg JWH-073 administration (Figure 4, bottom right), the overall ANOVA was 
significant (χ2=18.214, df=5, p<0.05) because every treatment day was significantly 
different from baseline trial (q=6.325, 5.422, 7.348, 5.237 and 8.083 for days 1–5, 
respectively, and q=5.480 for the trial after 2 week abstinence; p<0.05 for all comparisons.)
3.4 Cross-tolerance to hypothermic effects of SCBs in mice previously treated with Δ9-THC
As previously demonstrated (data replotted from Figure 3), Δ9-THC-naïve mice acutely 
administered 3.0 mg/kg JWH-018 or 10.0 mg/kg JWH-073 exhibited dramatic hypothermic 
effects which resolved within 3 to 5 hours (Figure 5, filled circles in top panels). In contrast, 
a profound attenuation of these hypothermic effects was observed in mice previously treated 
with 30.0 mg/kg Δ9-THC once per day for 4 consecutive days (Figure 5, grey squares in top 
panels) then tested with 3.0 mg/kg JWH-018 (F=87.905, df=2, p<0.05) or 10.0 mg/kg 
JWH-073 (F=41.345, df=2, p<0.05) on day 5. For Δ9-THC-treated mice tested with 3.0 
mg/kg JWH-018 (Figure 5, top left), the lowest temperature recorded was never below the 
species-typical range, and was significantly different from that observed in Δ9-THC-naïve 
mice (q=17.191, p<0.05). When these same mice were re-tested with 3.0 mg/kg JWH-018 
after a 14-day drug abstinence period, the lowest temperature recorded remained 
significantly different from that observed in Δ9-THC-naïve mice (q=15.081, p<0.05), but 
was not different from that observed during the initial cross-tolerance test (p>0.05). 
Similarly, for Δ9-THC-treated mice tested with 10.0 mg/kg JWH-073 (Figure 5, top right), 
the lowest temperature recorded was never below the species-typical range, and was 
significantly different from that observed in Δ9-THC-naïve mice (q=12.801, p<0.05). When 
these same mice were re-tested with 10.0 mg/kg JWH-073 after a 14-day drug abstinence 
period, the lowest temperature recorded remained significantly different from that observed 
in Δ9-THC-naïve mice (q=5.332, p<0.05), and was also different from that observed during 
the initial cross-tolerance test (q= 7.469, p<0.05).
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3.5 Lack of cross-tolerance to hypolocomotor effects of SCBs in mice previously treated 
with Δ9-THC
As previously demonstrated, Δ9-THC-naïve mice acutely administered 3.0 mg/kg JWH-018 
or 10.0 mg/kg JWH-073 exhibited profound suppression of locomotor activity during the 8 
hour post-injection period (Figure 5, bottom panels). Consistent with the previous findings 
of no tolerance to hypolocomotor effects, mice tested with either of the SCBs exhibited 
suppressed locomotor behavior relative to the baseline observation, regardless of Δ9-THC 
treatment history. For mice tested with 3.0 mg/kg JWH-018 (Figure 5, bottom left), motor 
activity was significantly different from that observed under the baseline condition in Δ9-
THC-naïve animals (q=7.682), in animals with a Δ9-THC history (q=8.824), and in these 
same animals when re-tested with 3.0 mg/kg JWH-018 after a 14-day drug abstinence period 
(q=6.215, p<0.05 for all comparisons.) No other between-group comparisons were 
statistically-significant (p>0.05 for all comparisons). Similarly, for mice tested with 10.0 
mg/kg JWH-073 (Figure 5, bottom right), motor activity was significantly different from 
that observed under the baseline condition in Δ9-THC-naïve animals (q=10.175), in animals 
with a Δ9-THC history (q=10.513), and in these same animals when re-tested with 10.0 
mg/kg JWH-073 after a 14-day drug abstinence period (q=10.187, p<0.05 for all 
comparisons.) No other between-group comparisons were statistically-significant (p>0.05 
for all comparisons).
3.6 Downregulation of CB1Rs in the hypothalamus but not the cortex after repeated CB 
treatment
To provide a mechanistic framework for behavioral findings, complementary ex vivo studies 
evaluating changes in CB1R expression (Figure 6) and function (Figure 7) in select brain 
regions were performed. Mice were treated for 4 days with either vehicle, Δ9-THC (30 mg/
kg), JWH-073 (10 mg/kg) or JWH-018 (3 mg/kg). One day after the last dose, brains were 
harvested, dissected into discrete regions, and membrane homogenates prepared to examine 
CB1R receptor binding (Figure 6). To estimate CB1R density, specific binding of the CB1R 
radioligand [3H]CP-55,940 (1nM) was determined in hypothalamic (Figure 6A) and cortical 
(Figure 6B) membranes. CB1Rs in hypothalami from untreated mice bound 1151 ± 45 
fmole/mg of [3H]CP-55,940. Consistent with CB1R downregulation, CB1Rs in hypothalami 
obtained from mice treated for 4 days with either Δ9-THC, JWH-073 or JWH-018 bound 
significantly less [3H]CP-55,940 (Figure 6A; p>0.05). In contrast, CB1R binding levels in 
mouse cortex homogenates did not change significantly from vehicle regardless of 
cannabinoid pretreatment (Figure 6B). These results indicate that CB1R downregulation 
does occur and it transpires in a region-specific manner.
3.7 Desensitization of CB1Rs in the hypothamlamus but not the cortex after repeated CB 
treatment
To determine the effects of repeated cannabinoid exposure on G-protein activation by 
CB1Rs, the [35S]GTPγS binding assay was employed (Figure 7). The capacity of a receptor 
saturating concentration of the full CB1R agonist JWH-018 (10 µM) to activate G-proteins 
was evaluated in hypothalamic (Figure 7A) and cortical (Figure 7B) membranes of 
chronically treated mice. Indicative of G-protein activation, JWH-018 produced a 51.8 ± 
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6.5% increase in binding of [35S]GTPγS to G-proteins in hypothalami from drug naïve mice. 
In contrast, JWH-018 produced less G-protein activation in hypothalami isolated from mice 
chronically treated with Δ9-THC or JWH-073, consistent with receptor desensitization 
(Figure 7A). Importantly, treatment of mice with Δ9-THC or JWH-073 did not desensitize 
CB1Rs in striatal membranes (Figure 7B), indicating that the adaptive changes produced by 
chronic treatment with phytocannabinoids or synthetic cannabinoids occur in a brain region 
specific manner. G-protein activation produced by JWH-018 (100 nM) in both brain regions 
was CB1R-dependent because it was completely blocked by co-incubation with the neutral 
CB1R antagonist O-2050 (1 µM, data not shown). Collectively, ex vivo receptor binding and 
functional data suggest that chronic treatment of mice with cannabinoids produces brain 
region-specific CB1R downregulation and desensitization.
4. Discussion
In these studies, complementary in vivo and ex vivo assays were used to compare the effects 
of repeated exposure to the low efficacy phytocannabinoid Δ9-THC and two high efficacy 
SCB drugs of abuse, JWH-018 and JWH-073. Initially, dose effect curves for hypothermic 
effects were generated after acute exposure to various doses of each drug in mice. Not 
surprisingly, all three cannabinoids produced dose-dependent hypothermic responses, 
similar to those previously reported for various CB1R agonists (e.g., CP-55,940 and WIN 
55,212-2) (Pertwee et al., 1993). Consistent with partial CB1 agonist effects, Δ9-THC-
induced hypothermia plateaued at 30 mg/kg, and 100 mg/kg Δ9-THC did not produce a 
greater response. In contrast, doses of JWH-018 and JWH-073 induced more extreme 
hypothermic effects than were ever observed with Δ9-THC, which is consistent with their 
relatively higher CB1 efficacy, as has been previously demonstrated ex vivo (Brents et al., 
2011; Brents et al., 2012). In addition, pretreatment with the low efficacy agonist Δ9-THC 
attenuated the hypothermic effects induced by subsequent administration of either higher 
efficacy SCB. Thus, congruent with previous work in other mouse strains (McMahon and 
Koek, 2007; Paronis et al., 2012), Δ9-THC exhibited characteristics of a partial agonist when 
administered alone, and when co-administered with a full agonist. Our present in vivo 
findings therefore replicate similar studies from other laboratories, and recapitulate the ex 
vivo profiles of Δ9-THC and the SCBs from our own previous experiments (Brents et al., 
2011; Brents et al., 2012).
Next, we sought to extend these in vivo profiles by assessing the development of tolerance 
and cross-tolerance to hypothermic and locomotor suppressant effects, two endpoints of the 
classical cannabinoid tetrad (i.e., Compton et al., 1992). Use of radiotelemetry probes 
allowed the simultaneous recording of core body temperature and locomotor activity in all 
subjects in order to assess tolerance to these two drug effects following repeated 
administration of low efficacy Δ9-THC or high efficacy SCBs, but the role of intrinsic 
efficacy in tolerance and cross-tolerance among the cannabinoids is underdeveloped and the 
data in this domain are often contradictory. For example, an early study demonstrated that 
mice repeatedly treated with Δ9-THC (20 mg/kg, once a day for 2 days) showed a 6-fold 
tolerance to the hypothermic effects of subsequent Δ9-THC, and a similar degree of 
tolerance (approximately 5-fold) was observed for the hypothermic effects of high efficacy 
cannabinoids CP-55,940 and WIN 55,212-2 (Pertwee et al., 1993). However, a different 
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regimen of Δ9-THC (10 mg/kg, twice per day for 6 days) resulted in approximately 10-fold 
shifts in subsequent Δ9-THC dose effect curves for motor activity, hypothermia and 
antinociception in mice, but only moderate tolerance was apparent when high efficacy 
cannabinoids CP-55,940 or WIN 55,212-2 were tested, and only to some of these effects 
(Fan et al., 1994). Finally, and most relevant to the present study, Δ9-THC treatment (1 
mg/kg, every day for 3 days) decreased sensitivity to the discriminative stimulus effects of 
Δ9-THC 3-fold, but did not alter the Δ9-THC-like interoceptive effects of high efficacy 
cannabinoids CP-55,940, JWH-073, or JWH-018 in rhesus monkeys, although prolonged 
Δ9-THC treatment reduced sensitivity to the Δ9-THC-like discriminative stimulus effects of 
all cannabinoids (Hruba et al., 2012). Importantly, the tolerance observed to the effects of 
high efficacy compounds was approximately 50% less than that observed for Δ9-THC itself 
(Hruba et al., 2012).
In the present study, cannabinoid efficacy did not appear to dramatically affect the 
development of tolerance to hypothermic effects. Whether mice were chronically treated 
with low efficacy Δ9-THC or with high efficacy JWH-018 or JWH-073, tolerance developed 
within 5 days of regular treatment and was still evident 2 weeks after the last cannabinoid 
injection. Previous reports show tolerance to Δ9-THC-induced hypothermia develops 
rapidly, and is often observed as early as the second treatment (Pertwee et al., 1993). In 
addition, McMahon and colleagues reported that tolerance to cannabinoid-induced 
hypothermia was still present 9 days after last treatment (Singh et al., 2011). Interestingly, 
tolerance does not develop to all cannabinoid effects. Here we demonstrated dramatic 
tolerance to hypothermic effects in the very same animals in which locomotor activity 
remained profoundly suppressed throughout the study. This finding is not necessarily 
consistent with previous studies, in which tolerance to locomotor suppressant effects is often 
observed. For instance, 14 days of continuous exposure to the synthetic Δ9-THC analogue 
HU-210 (3-(1,1’-dimethylheptyl)-6aR,7,10, 10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
dibenzo[b,d]pyran-9-methanol) resulted in clear tolerance to hypomotility in the rat 
(Caberlotto et al., 2004). It may be the case that tolerance to hypomotility develops at a 
slower rate than tolerance to hypothermia, in which case a longer treatment period than the 
one presently employed may be required to observe this effect. Another possibility is that 
our method of measuring activity using radiotelemetry probes in a home cage setting may be 
less sensitive than other devices that measure motor activity. Using our system, baseline 
activity levels are extremely low, and in order to observe dose-related suppression of motor 
activity we must place our subjects in new cages with fresh bedding immediately after 
injection. This stimulates exploratory behavior in control subjects, which is reliably 
suppressed by cannabinoid administration. The phenomenon of locomotor sensitization is 
often conceptualized as “reverse tolerance”, and the arousal state of an animal is an 
important determinant of locomotor sensitization (Martin-Iverson et al., 1988). Similarly, 
environmental novelty can also dramatically modulate locomotor sensitization, minimizing 
its expression in environments similar to the home cage, and maximizing its expression in 
environments distinct from the home cage (Badiani et al., 1995). We are not aware of 
studies directly testing whether these same relationships also apply to tolerance to locomotor 
effects, but assessment of acute and chronic drug effects on locomotor activity within a 
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home cage environment is certainly likely to differ from similar experiments using 
environmentally distinct and novel activity chambers.
Much of our understanding of tolerance and cross-tolerance has been achieved by 
investigating these effects among opioids, where it has been determined that there is an 
inverse relationship between intrinsic efficacy and tolerance / cross-tolerance. For example, 
using an assay of morphine discrimination in rats, Young and colleagues (1991) found that a 
regimen of twice-daily treatment with morphine increased the ED50 for high efficacy 
opioids etorphine, methadone and buprenorphine by only 2- to 4-fold, while inducing an 
apparently insurmountable tolerance to the morphine-like interoceptive effects of the low 
efficacy opioid nalbuphine. In squirrel monkeys, daily morphine treatment shifted the dose 
effect curve for the rate-decreasing effects of morphine, but produced significantly smaller 
shifts in the dose effect curves for higher efficacy opioids such as etorphine, l-methadone, 
and sufentanil (Hughes et al., 1995). Similarly, daily administration of morphine in an assay 
of schedule-controlled responding in rats shifted the morphine dose-effect curve to the right, 
but produced a 3-fold larger shift in the dose-effect curve for the low efficacy opioid 
butorphanol (Hughes et al., 1995). Subsequent work (Smith and Picker, 1998) demonstrated 
that tolerance to rate-decreasing effects induced by repeated butorphanol treatments were 
surmounted by administration of high efficacy opioids fentanyl and sufentanil in the rat. The 
role of intrinsic efficacy in tolerance to the analgesic effects of opioids has also been 
investigated, and rats made tolerant to analgesic effects of morphine or fentanyl (as 
evidenced by shifts in their respective dose effect functions) were completely insensitive to 
analgesic effects of the low efficacy opioids buprenorphine, levorphanol and meperidine 
(Paronis and Holtzman, 1992). This same pattern of effects has also been observed with 
regard to respiratory depressant effects of opioids in mice, where tolerance to respiratory 
depression induced by implantation of subcutaneous morphine pellets was overcome by 
subsequent intracerebroventricular administration of high efficacy opioids etorphine and 
heroin (Roerig et al., 1987).
However, among the cannabinoids used in the present study, high efficacy agonists 
JWH-018 and JWH-073 were unable to induce hypothermia in mice previously made 
tolerant to hypothermic effects of low efficacy Δ9-THC, suggesting that cross-tolerance 
developed to the hypothermic effects of the high efficacy SCBs, despite the relatively large 
disparity in intrinsic activity. In other words, unlike what is typically observed with opioids, 
tolerance to an effect induced by low efficacy Δ9-THC was not surmounted by 
administration of either high efficacy SCB. Furthermore, cross-tolerance was still present 14 
days after Δ9-THC cessation, suggesting that this cross-tolerance may be as persistent as the 
tolerance induced by repeated administration of the high efficacy SCBs themselves. In 
contrast, since tolerance to cannabinoid-induced hypomotility did not occur with repeated 
administration of any of the three drugs utilized in these experiments, it was not surprising 
that there was no cross-tolerance to hypomotility when JWH-018 and JWH-073 were 
administered after repeated Δ9-THC. Thus, our present work suggests that cross-tolerance 
does occur among cannabinoid agonists of differing efficacy; however, previous studies 
have demonstrated that the degree of cross-tolerance observed is often variable across 
different endpoints. In non-human primates, chronic Δ9-THC (1 mg/kg, every 12 hours) 
elicited marked tolerance (23- and 160-fold) to the effects of subsequent Δ9-THC on 
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schedule-controlled responding, but induced lesser cross-tolerance (approximately 10-fold) 
to the effects of the full CB1 agonists CP-55,940 and WIN 55,212-2 on these same 
endpoints; however, while this regimen of Δ9-THC treatment reduced sensitivity to the 
discriminative stimulus effects of subsequent Δ9-THC, no cross-tolerance to these effects 
was observed when CP-55,940 and WIN 55,212-2 were tested (McMahon, 2011). In 
subsequent experiments in the mouse, chronic Δ9-THC treatment (32 mg/kg/day) resulted in 
tolerance to rate-decreasing and hypothermic effects of subsequent Δ9-THC, but cross-
tolerance to CP-55,940 was only observed for hypothermic effects (Singh et al., 2011). 
McMahon (2011) has proposed that cannabinoid agonist efficacy has an inverse relationship 
with tolerance and cross-tolerance, similar to what is observed in the opioid system, 
although our present results fail to support that notion. Further investigation will be required 
to determine whether these disparate results are due to differences in dosing regimens, 
species-specific factors, pharmacokinetic variables, or the drugs themselves and how they 
may differ in their interactions with cannabinoid and non-cannabinoid binding sites.
In this regard, to begin to understand the mechanisms behind our present findings, ex vivo 
CB1R binding and functional studies were also carried out in homogenates from discrete 
brain regions of mice chronically treated with Δ9-THC or the high efficacy SCBs. It has 
been previously demonstrated that adaptive cellular events including downregulation and 
desensitization of CB1Rs mediate tolerance to cannabinoid effects (Sim-Selley, 2003); 
therefore, our studies incorporated both competition receptor binding and [35S]GTPγS 
binding experiments to measure CB1R density and function, respectively. Repeated 
cannabinoid exposure induced a dramatic downregulation of CB1R expression in the 
hypothalamus, which is a critical brain region for thermoregulation. This reduction in CB1R 
availability in the hypothalamus may explain the profound tolerance presently observed to 
hypothermic effects of repeated cannabinoid administration. In contrast, CB1R expression in 
the cortex was not altered by repeated cannabinoid exposure, which may partially explain 
the lack of tolerance to hypomotility observed in mice. These observations are consistent 
with previous studies in humans demonstrating that prolonged marijuana exposure results in 
region-specific downregulation of central CB1Rs (Hirvonen et al., 2011). Since CB1R 
expression was profoundly reduced in the hypothalamus but not in the cortex, the function 
of remaining CB1Rs in these brain regions was further examined by agonist activation of G-
proteins. As predicted by previous studies (Rinaldi-Carmona et al., 1998; Sim-Selley, 2003), 
CB1R-mediated G-protein activation was greatly desensitized by repeated cannabinoid 
exposure. Interestingly, the extent of CB1R downregulation and desensitization observed in 
the hypothalamus were not related to the efficacy of the cannabinoid used to induce these 
effects. Indeed, the effects of repeated Δ9-THC on CB1R expression and function were at 
least as pronounced as those of repeated exposure to the two high efficacy SCBs. Further 
mechanistic studies will be required to more fully understand the biochemical basis of CB1R 
downregulation and desensitization, but recent evidence suggests an important role for p-
arrestin2 (Imperatore et al., 2015)
5. Conclusion
Finally, although the role of tolerance in drug abuse is incompletely understood, it is 
supposed that tolerant users may escalate drug dose to overcome reduced effectiveness of 
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the drug of abuse. In the case of SCBs, use of these compounds is associated with significant 
toxicity (e.g., Fantegrossi et al., 2014), although the mechanisms for these adverse effects 
are still unclear. Nevertheless, regardless of mechanism, tolerance to drug effects might be 
expected to lead to increased drug exposure as users escalate their doses, thus also 
increasing their risk for serious adverse effects. Given that most college students who abuse 
SCBs also report use of marijuana (Hu et al., 2011; Vandrey et al, 2012), cross tolerance of 
the sort described in these studies may also be a critical factor in mediating dose selection of 
these emerging drugs of abuse. As abuse of these high efficacy SCBs continues, a thorough 
understanding of the acute and chronic effects of these substances is critical in order to 
inform both drug policy and clinical management of users who present with symptoms of 
SCB-induced toxicity.
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Structures of Δ9-THC (left) and the aminoalkylindole cannabinoids JWH-018 and JWH-073 
(right).
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Left panel: Maximal hypothermic effects following Δ9-THC, JWH-018 or JWH-073 in mice 
(n=5 per drug, per dose). Abscissa: dose of drug, in mg/kg, expressed on a log scale. 
Ordinate: lowest core temperature achieved, in °C, as measured via radiotelemetry. Absence 
of error bars indicates an instance where the variability is contained within the point. 
Asterisks indicate significant differences from lower doses, within drug. Hash marks 
indicate significant differences from JWH-073, within dose. Bullseyes indicate significant 
differences from Δ9-THC, within dose. Right panel: Maximal hypothermic effects of 30 
mg/kg Δ9-THC, 3 mg/kg JWH-018 or 10 mg/kg JWH-073 in mice (n=5 per group) 
pretreated with saline (white) or 30 mg/kg Δ9-THC (black) 60 min prior. Asterisks indicate 
significantly different values from the saline+Δ9-THC group.
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Effects of daily administration of saline (upper left), 30 mg/kg Δ9-THC (upper right), 3 
mg/kg JWH-018 (bottom left) or 10 mg/kg JWH-073 (bottom right) on core temperature in 
mice (n=5 per group). Only data from days 1 (black circles) and 5 (grey squares), and after 
14 days of cannabinoid abstinence (inverted triangles) are shown. Abscissa: time after drug 
injection, in minutes. Ordinate: core temperature, in °C, as measured via radiotelemetry. 
Absence of error bars indicates an instance where the variability is contained within the 
point. For statistical comparisons, please see section 3.2.
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Effects of daily administration of saline (upper left), 30.0 mg/kg Δ9-THC (upper right), 3.0 
mg/kg JWH-018 (bottom left) or 10.0 mg/kg JWH-073 (bottom right) on locomotor activity 
in mice (n = 6 per group). Data from all 5 days of injection are presented (black circles), 
along with a vehicle injection control point (open square) and a point obtained after 14 days 
of cannabinoid abstinence (open circle.) Abscissa: injection condition. Ordinate: mean total 
activity counts for 8 hours after injection, as measured via radiotelemetry. Absence of error 
bars indicates an instance where the variability is contained within the point. Asterisks 
indicate significant differences from baseline.
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Top - Effects of acute administration of 3.0 mg/kg JWH-018 (left) or 10.0 mg/kg JWH-073 
(right) on core temperature in mice (n = 5 or 6), as a function of Δ9-THC history. Black 
circles represent hypothermia elicited by the SCBs in previously drug-naïve mice, while 
grey squares depict the analogous data obtained from mice previously treated with Δ9-THC 
(see section 2.2) Inverted triangles illustrate the thermoregulatory effects of a second 
injection of 3.0 mg/kg JWH-018 (left) or 10.0 mg/kg JWH-073 (right) in mice previously 
treated with Δ9-THC after 14 days of cannabinoid abstinence. All other graph properties as 
described in Figure 3. Please see section 3.4 and 3.5 for statistical comparisons. Bottom - 
Effects of acute administration of 3.0 mg/kg JWH-018 (left) or 10.0 mg/kg JWH-073 (right) 
on locomotor activity in mice (n = 6), as a function of Δ9-THC history. Bars represent mean 
total activity quantified for 8 hours after injection. Asterisks indicate significant differences 
from baseline observations.
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Region-specific downregulation of CB1Rs in mouse hypothalamus (top), but not cortex 
(bottom), following administration of vehicle (black), 30 mg/kg Δ9-THC (white), 10 mg/kg 
JWH-073 (striped) or 3 mg/kg JWH-018 (grey) in mice (n = 4 per group), once per day for 4 
days. Values designated with different letters above the error bars are significantly different 
(P<0.05, one-way ANOVA followed by a Tukey’s post-hoc test, mean ± SEM).
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Desensitization of CB1Rs in mouse hypothalamus (top), but not cortex (bottom), when 
stimulated with a receptor-saturating concentration (10 µM) of JWH-018. Prior to tissue 
harvesting, mice (n = 4 per group) were treated with vehicle (black), 30 mg/kg Δ9-THC 
(white) or 10 mg/kg JWH-073 (striped), once per day for 4 days. Values designated with 
different letters above the error bars are significantly different (P<0.05, one-way ANOVA 
followed by a Tukey’s post-hoc test, mean ± SEM).
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